MYGN (Myriad Genetics) Change In Payables And Accrued Expense : $-72.8 Mil (TTM As of Sep. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Change In Payables And Accrued Expense?

Myriad Genetics's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $3.0 Mil. It means Myriad Genetics's Accounts Payable & Accrued Expense increased by $3.0 Mil from Jun. 2024 to Sep. 2024 .

Myriad Genetics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $23.7 Mil. It means Myriad Genetics's Accounts Payable & Accrued Expense increased by $23.7 Mil from Dec. 2022 to Dec. 2023 .

Myriad Genetics Change In Payables And Accrued Expense Historical Data

The historical data trend for Myriad Genetics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Change In Payables And Accrued Expense Chart

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.30

-6.30

74.90

-84.70

23.70

Myriad Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															12.70	-65.10	-8.60	-2.10	3.00

Myriad Genetics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.8 Mil.

Myriad Genetics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

CDNA OPK CSTL NEO GRAL FLGT TWST ACRS ATLN PSNL TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

0K3W:UK MYD:Germany MYD:Germany MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Executives

Paul J Diaz	director, officer: President and CEO	680 SOUTH FOURTH STREET, LOUISVILLE KY 40202
Dale Muzzey	officer: Chief Scientific Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Reitan Colleen F	director	300 THIRD STREET, CAMBRIDGE MA 02142
Margaret Ancona	officer: SVP, Chief of Staff	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Rashmi Kumar	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Richard Bryan Riggsbee	officer: Chief Financial Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Nicole Lambert	officer: Chief Operating Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong	officer: Chief Legal Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman	officer: Chief People Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro	director
Kevin Richard Haas	officer: Chief Technology Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk	officer: Chief Accounting Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116